ArticleInternational journal of clinical and experimental pathology2018
P1-HNF4α expression negatively correlates with HER2 levels and is associated with good prognosis in gastric adenocarcinoma.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HNF4α, a member of the steroid/thyroid nuclear receptor super family, is a transcriptional factor expressed in various tissues and cells. In this study, we aimed to investigate the clinical significance of P1-HNF4α protein expression in gastric adenocarcinoma. We examined P1-HNF4α and HER2 protein levels in the tissue of 245 gastric adenocarcinoma samples by immunohistochemistry, and analyzed the association between P1-HNF4α levels, and clinicopathologic factors or prognosis. In gastric adenocarcinoma, positive staining of P1-HNF4α was shown in 150 (61.2%) of 245 cases, while positive expression of HER2 was shown in 36 (14.7%) of 245 cases as detected by immunohistochemistry. The expression of P1-HNF4α was negatively correlated with that of HER2. Furthermore, P1-HNF4α and HER2 highly expressed in intestinal-type adenocarcinoma according to the Lauren classification, tubular adenocarcinoma according to WHO classification, and well-to-moderately differentiated tumors. In gastric adenocarcinoma, P1-HNF4α was significantly associated with histological type, Lauren grade, degree of tumor differentiation, vascular invasion, lymph node metastases, and pTNM stage. Moreover, survival analysis showed that P1-HNF4α expression was an independent prognostic factor of good survival in gastric adenocarcinoma (P<0.05). Our results indicate that a negative correlation exists between P1-HNF4α and HER2 expression levels and P1-HNF4α is significantly correlated with tumor progression and a good prognosis in gastric adenocarcinoma.
Indexed as
Identifiers
31949800PMC6962818W3028128411What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.